Trevi Therapeutics Inc (TRVI) Stock Price, Quote & News

Company Profile

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough i...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 304 2499

Website: www.trevitherapeutics.com

Address:

195 Church Street, 16th Floor, New Haven, United States

Bfunk17 Oct. 24 at 8:20 PM

$TRVI Institutional Ownership ticked up to 103.4% on Fintel. It is very interesting how they keep accumulating here at these levels. Love it.

0 · Reply

KINGKASHH Oct. 24 at 11:12 AM

$TRVI when the whole market dipped, this did not.

0 · Reply

ZR92x Oct. 23 at 8:23 PM

$TRVI Top 3 buyout candidates (in no particular order) - 1) Boehringer Ingelheim 2) Merck 3) Insmed

1 · Reply

Soheil444 Oct. 21 at 7:45 PM

$TRVI you’re a beast! too bad for ppl who dont know about this treasure

2 · Reply

Soheil444 Oct. 16 at 2:00 PM

$TRVI beautiful

0 · Reply

Bfunk17 Oct. 15 at 9:09 PM

$TRVI Stay solid my friends. Buyout is coming for us. Everything is coming together here. Be patient. GL to you.

2 · Reply

abcdzepeda Oct. 15 at 7:11 PM

$TRVI 11.00 by EOD?

0 · Reply

ZR92x Oct. 15 at 1:42 PM

$TRVI News imminent?

0 · Reply

JFDI Oct. 15 at 1:23 PM

$TRVI @Doozio yo long this thing? mjthwaites on X all over it.

2 · Reply

abcdzepeda Oct. 14 at 5:04 PM

$TRVI We running!

0 · Reply

Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting

Sep 18, 2025, 7:30 AM EDT - 5 weeks ago

Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025

Sep 9, 2025, 7:15 PM EDT - 6 weeks ago

Trevi Therapeutics, Inc. (TRVI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Aug 28, 2025, 7:30 AM EDT - 2 months ago

Trevi Therapeutics to Participate in Upcoming September Conferences

Aug 8, 2025, 1:47 PM EDT - 2 months ago

Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 2 months ago

Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 31, 2025, 4:05 PM EDT - 3 months ago

Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

Jul 29, 2025, 7:30 AM EDT - 3 months ago

Trevi Therapeutics to Participate in Upcoming August Conferences

Jul 1, 2025, 7:30 AM EDT - 4 months ago

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism

Jun 5, 2025, 4:30 PM EDT - 5 months ago

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Jun 3, 2025, 10:15 PM EDT - 5 months ago

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

Jun 2, 2025, 4:01 PM EDT - 5 months ago

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

Jun 2, 2025, 1:42 PM EDT - 5 months ago

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients

Jun 2, 2025, 7:00 AM EDT - 5 months ago

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

Jun 1, 2025, 4:00 PM EDT - 5 months ago

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

May 29, 2025, 7:30 AM EDT - 5 months ago

Trevi Therapeutics to Participate in Upcoming June Conferences

$Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough$

May 20, 2025, 7:00 AM EDT - 5 months ago

Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

May 11, 2025, 4:16 AM EDT - 5 months ago

Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 6 months ago

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

May 1, 2025, 4:05 PM EDT - 6 months ago

Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

Apr 3, 2025, 7:30 AM EDT - 7 months ago

Trevi Therapeutics to Participate in Upcoming April Investor Conferences

Mar 18, 2025, 6:47 PM EDT - 7 months ago

Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 4:05 PM EDT - 7 months ago

Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

Mar 11, 2025, 4:05 PM EDT - 8 months ago

Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025

Mar 10, 2025, 11:30 AM EDT - 8 months ago

Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps

$Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough$

Mar 10, 2025, 6:00 AM EDT - 8 months ago

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

$Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough$

Mar 9, 2025, 4:00 PM EDT - 8 months ago

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Feb 27, 2025, 7:30 AM EST - 8 months ago

Trevi Therapeutics to Participate in Upcoming March Investor Conferences

Feb 25, 2025, 7:30 AM EST - 8 months ago

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Jan 30, 2025, 7:30 AM EST - 9 months ago

Trevi Therapeutics to Participate in Upcoming February Investor Conferences

Jan 8, 2025, 7:30 AM EST - 10 months ago

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Dec 16, 2024, 7:36 AM EST - 11 months ago

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

Dec 12, 2024, 9:47 AM EST - 11 months ago

Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?

Dec 12, 2024, 7:30 AM EST - 11 months ago

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Dec 3, 2024, 4:05 PM EST - 11 months ago

Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine

Nov 21, 2024, 7:30 AM EST - 1 year ago

Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Nov 6, 2024, 11:54 PM EST - 1 year ago

Trevi Therapeutics, Inc. (TRVI) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 1 year ago

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Oct 30, 2024, 4:05 PM EDT - 1 year ago

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024

$Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough$

Oct 21, 2024, 7:30 AM EDT - 1 year ago

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough

Oct 15, 2024, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences

Oct 3, 2024, 4:05 PM EDT - 1 year ago

Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program

Sep 30, 2024, 5:30 PM EDT - 1 year ago

Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D.

Sep 26, 2024, 7:30 AM EDT - 1 year ago

Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024

Aug 28, 2024, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Participate in September Investor and Medical Conferences

Aug 11, 2024, 1:28 AM EDT - 1 year ago

Trevi Therapeutics, Inc. (TRVI) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024

Bfunk17 Oct. 24 at 8:20 PM

$TRVI Institutional Ownership ticked up to 103.4% on Fintel. It is very interesting how they keep accumulating here at these levels. Love it.

0 · Reply

KINGKASHH Oct. 24 at 11:12 AM

$TRVI when the whole market dipped, this did not.

0 · Reply

ZR92x Oct. 23 at 8:23 PM

$TRVI Top 3 buyout candidates (in no particular order) - 1) Boehringer Ingelheim 2) Merck 3) Insmed

1 · Reply

Soheil444 Oct. 21 at 7:45 PM

$TRVI you’re a beast! too bad for ppl who dont know about this treasure

2 · Reply

Soheil444 Oct. 16 at 2:00 PM

$TRVI beautiful

0 · Reply

Bfunk17 Oct. 15 at 9:09 PM

$TRVI Stay solid my friends. Buyout is coming for us. Everything is coming together here. Be patient. GL to you.

2 · Reply

abcdzepeda Oct. 15 at 7:11 PM

$TRVI 11.00 by EOD?

0 · Reply

ZR92x Oct. 15 at 1:42 PM

$TRVI News imminent?

0 · Reply

JFDI Oct. 15 at 1:23 PM

$TRVI @Doozio yo long this thing? mjthwaites on X all over it.

2 · Reply

abcdzepeda Oct. 14 at 5:04 PM

$TRVI We running!

0 · Reply

lob11 Oct. 14 at 4:51 PM

$TRVI Finally broke 10. Need some follow thru

0 · Reply

ZR92x Oct. 14 at 3:41 PM

$TRVI Someone just dropped $5 million today buying 500,000 shares at $10 just a bit ago. Nice price action today. Also....I did some analysis on the unusual call options activity back in August for the September 19th expiry. Remember the 15,000 call options open interest in Trevi call options last month? Well.. that same day in late August when someone was going ham on Trevi options buying the 15,000 September 19th $7 call options, there was also unusual call options buying activity for Protagonist Therapeutics for the same September 19th dated expiry. Just last Friday, Johnson and Johnson just announced they are in talks to to buyout Protagonist Therapeutics (PTGX). Coincidence? Maybe, but we shall see...

2 · Reply

Bfunk17 Oct. 13 at 9:45 PM

$TRVI Following up on ZR92x's excellent DD: How Boehringer Ingelheim is buttressing its US business | Fierce Pharma https://share.google/Amkx5S6jqgTMJfwEv Interview audio is available in middle of the page. Boehringer US head said a few very intriguing things: -They love launching new drugs -They want to be #1 in IPF as ZR92x pointed out -They prefer to buy preclinical entities, not FDA approved or late-stage molecules/drugs Everything they said fits Trevi as a potential BO target.

0 · Reply

ZR92x Oct. 13 at 1:39 PM

$TRVI Executive with Boehringer Ingelheim just did an interview with Fierce Pharma and said Boehringer wants to become an industry leader in the IPF space with Ofev and their just newly approved IPF drug. They just canceled their chronic cough drug in Phase 2 because the results were bad after they did a futility analysis at 4 weeks in. They need to acquire Trevi to get into chronic cough or else they wont be the leaders with a best in class IPF portfolio

1 · Reply

Bfunk17 Oct. 11 at 2:06 PM

$TRVI Trevi Therapeutics Completes Key Phase 1 Drug Interaction Study - TipRanks.com https://share.google/U9Jjm8wb6avCUMi7F

2 · Reply

jlcrane Oct. 10 at 7:50 PM

$TRVI Let's close above the IPO price, finally.

1 · Reply

abcdzepeda Oct. 9 at 12:32 AM

$TRVI TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the acceptance of two abstracts for presentation at the CHEST 2025 Annual Meeting, to be held from October 19 to 22 in Chicago, Illinois.

0 · Reply

Bfunk17 Oct. 7 at 2:44 PM

$TRVI Non-IPF ILD protocol meeting results with FDA due any day. Additionally, trial design talks with FDA for P3 IPF. Both of these PRs should be incoming over the next 2 months and set up Trevi for its future. Of course, landing the non-IPF design with the FDA would be tremendous. Haduvio would be lined up for 3 indications if this comes through.

0 · Reply

Bfunk17 Oct. 5 at 12:31 PM

$TRVI Updated this morning. Continued powerful accumulation and Tute ownership here.

1 · Reply

SweepCastApp Oct. 3 at 7:48 PM

$TRVI: Unusual Options Activity Alerted CALL flow observed 250x contracts at Strike price of $3 Exp on 01/21/2028 with Premium of $180K and showing NEUTRAL Sentiment

1 · Reply

Bfunk17 Oct. 3 at 2:42 PM

$TRVI Solid movement upward as expected. Looking good overall.

2 · Reply

Bfunk17 Oct. 1 at 12:41 AM

$TRVI Really nice build occurring here. The 1-year is powerful combined with whispers of an incoming BO. Time will tell...but this company's science is incredibly impressive. 🤝

0 · Reply

Market Cap	1.30B
Revenue (ttm)	0.00
Net Income (ttm)	-47.91M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,113,200
Avg Vol	2,326,162
Day's Range	N/A - N/A
Shares Out	121.78M
Stochastic %K	67%
Beta	0.74
Analysts	Strong Sell
Price Target	$20.36